SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001104659-23-101236
Filing Date
2023-09-15
Accepted
2023-09-15 16:45:14
Documents
2
Period of Report
2023-09-14

Document Format Files

Seq Description Document Type Size
1 OWNERSHIP DOCUMENT tm2326155d1_3.html 3  
1 OWNERSHIP DOCUMENT tm2326155d1_3.xml 3 1552
2 POWER OF ATTORNEY tm2326155d1_ex24-1.htm EX-24.1 5311
  Complete submission text file 0001104659-23-101236.txt   8477
Mailing Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601
Business Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601 201-696-9345
Protalix BioTherapeutics, Inc. (Issuer) CIK: 0001006281 (see all company filings)

IRS No.: 650643773 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address C/O EDDEVA B920 BABRAHAM RESEARCH CAMPUS CAMBRIDGE X0 CB22 3AT
Business Address
Forster Eliot (Reporting) CIK: 0001831558 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-33357 | Film No.: 231259246